Memantin Goodwill (Memantine Hydrochloride)

Memantine hydrochloride blocks the NMDA receptor’s ion channel in a non‑competitive manner, reducing excessive calcium entry caused by glutamate over‑activation. This limits excitotoxic neuronal damage that contributes to the progression of Alzheimer’s disease.

The dose of Memantin Goodwill is determined individually by a qualified prescriber based on the patient’s clinical condition, renal function, and tolerability. No fixed regimen is provided here.

Safety data for memantine during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantin Goodwill belongs to the NMDA antagonist class, whereas drugs such as donepezil or rivastigmine are acetylcholinesterase inhibitors. Memantine is typically used for moderate to severe disease and may be combined with an inhibitor for broader symptom control.

Store the product below 25 °C in its original container, protected from moisture and direct sunlight. Keep out of reach of children and do not use after the expiry date.

Memantin Goodwill is taken orally as a tablet. The tablet should be swallowed whole with water and can be taken with or without food, following the prescriber’s instructions.

Serious adverse reactions include seizures, severe allergic responses, cardiac arrhythmias, hepatic dysfunction, and psychosis. Patients should seek immediate medical attention if any of these events occur.

Memantin Goodwill is contraindicated in patients with known hypersensitivity to memantine or any excipients, and it should be used with caution in individuals with severe renal impairment, uncontrolled epilepsy, or significant cardiac disease.